HK Stock Market Move | XUANZHUBIO-B(02575) surged by over 5% approaching previous high. Its innovative drug Xuanyue Ning was included in the national basic medical insurance drug list for the first time.

XuanzhuBio-B (02575) rose over 5% in the morning session, reaching a high of 71.9 Hong Kong dollars, approaching the historical high of 72 Hong Kong dollars. As of the time of publication, it was up 4.42% at 70.8 Hong Kong dollars, with a trading volume of 2202.11 million Hong Kong dollars. On the news front, Xuanzhu Bio's innovative drug Xuan Yening was included in the national basic medical insurance drug list for the first time. The results of this medical insurance negotiation will help improve the affordability and accessibility of Piloceryl tablets among patients, promote the promotion and sales scale of the drug market, and thereby have a positive impact on the long-term business development of Xuanzhu Bio. Public information shows that Pirocycin tablets, as a novel CDK2/4/6 inhibitor, have the advantage of effectively inhibiting the proliferation of tumor cells and have been approved by the China National Medical Products Administration in May 2025 for specific types of advanced or metastatic breast cancer patients. Its two approved indications have been included in the 2025 national basic medical insurance list. In addition, the marketing application for the first-line treatment indication of Pirocycin in combination with aromatase inhibitors is under review.